H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 20.82 HKD -2.16% Market Closed
Market Cap: 18.2B HKD

Operating Margin
HUTCHMED (China) Ltd

-3.3%
Current
-29%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3.3%
=
Operating Profit
-19.7m
/
Revenue
602.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
HK
HUTCHMED (China) Ltd
HKEX:13
18.2B HKD
-3%
US
Eli Lilly and Co
NYSE:LLY
996.3B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
512.5B USD
27%
CH
Roche Holding AG
SIX:ROG
255.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.7B GBP
24%
CH
Novartis AG
SIX:NOVN
205.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
250.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
149B USD
29%
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
18.2B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.

Intrinsic Value
27.88 HKD
Undervaluation 25%
Intrinsic Value
Price
H
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3.3%
=
Operating Profit
-19.7m
/
Revenue
602.2m
What is the Operating Margin of HUTCHMED (China) Ltd?

Based on HUTCHMED (China) Ltd's most recent financial statements, the company has Operating Margin of -3.3%.

Back to Top